Facebook
Twitter
LinkedIn
ForwardPulse: You take my breath away: Tenecteplase for the treatment of acute pulmonary embolism
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Currently, TNK is approved for myocardial infarction only, but is used off label in therapy for ischemic strokes. TNK is a viable alternative to alteplase in acute PE and would be beneficial in practice due to its ability to be an IV push
Target Audience
Pharmacist
Learning Objectives
• Define the pathophysiology and classification of acute pulmonary embolism
• Describe the data for the use of tenecteplase in pulmonary embolism
• Discuss tenecteplase’s place in therapy in comparison to current guideline directed therapy
Additional Information
| Attachment | Size |
|---|---|
 Audience Disclosure slide_30.pptx | 460.3 KB |
 PULSE Handout.pdf | 75.16 KB |
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Currently, TNK is approved for myocardial infarction only, but is used off label in therapy for ischemic strokes. TNK is a viable alternative to alteplase in acute PE and would be beneficial in practice due to its ability to be an IV push
Abigail Cochran, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.